Saturna Capital’s Quince Therapeutics QNCX Stock Holding History

Saturna Capital’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-26	Closed	-$468K	–	178
2021 Q3	$468K	Hold	26	–	–	0.01%	135
2021 Q2	$277K	Buy	+26	New	+$218K	0.01%	159

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Saturna Capital's QNCX Position: Q4 2021 in Review

Saturna Capital sold out of Quince Therapeutics (QNCX) in Q4 2021, closing a stake of 26 shares — an estimated $468K sold.

Saturna Capital first reported a position in QNCX in Q2 2021 and held it in 2 quarters. The position peaked at $468K in Q3 2021. 97 funds tracked by Wall St. Rank hold QNCX as of Q4 2021.

Saturna Capital reported no remaining Quince Therapeutics position as of Q4 2021 after selling out during the quarter.
Saturna Capital sold 26 Quince Therapeutics shares in Q4 2021, an estimated $468K.
Saturna Capital first reported a position in Quince Therapeutics in Q2 2021 and held it in 2 quarters.
Saturna Capital's Quince Therapeutics position peaked at $468K in Q3 2021.
97 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2021.

Based on Saturna Capital's 13F filing for Q4 2021, filed 9 Feb 2022.